7EL-SADR W M, PERLMAN D C, MATTS J P, et al.Evaluation of an intensive intermittent-induction regimen and duratfon of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis[J]. Gin Infect Dis, 1998,26(5) : 1148-1158.
9Masur H. Approach to the patient with human immunodeficiency virus infection: clinical features. In : Gorbaeh SL (eds) [ M ]. Infectious Disease. 2th Ed, London : W. B. Saunders, 1998 : 1052 - 1062.
10Girardi E, Palmieri F,Cingulani A,et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antirctroviral therapy [J] .J Acquir Immune Defic Syndr,2001,26:326 - 331.
6Fang Z,Doig C,Rayner A.et al.Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990 to 1997)[J].J Clin Microbiol,1999,37 (4):998-1003.
7Ramaswamy SV,Amin AG,Goksel S.Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis[J].Antimicrob Agents Chemother,2000,44 (2):326-336.
8Burkardt HJ.Standardization and quality control of PCR analyses[J].Clin Chem Lab Med,2000,38(2):87-91.
9Soini H,Musser JM.Molecular diagnosis of mycobacteria[J].Clin Chem,2001,47(5):809-814.
10Pablos-Mendez A,Raviglione MC,Laszlo A,et al.Global surveillance for antituberculosis-drug resistance,1994-1997.World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on AntiTuberculosis Drug Resistance Surveillance[J].N Engl J Med,1998,338(23):1641-1649.
